Gündüz Kaan, Bakri Sophie J
Department of Ophthalmology, Faculty of Medicine, Ankara University, Ankara, Turkey.
Compr Ophthalmol Update. 2007 Sep-Oct;8(5):245-56.
Proliferative diabetic retinopathy is characterized by neovascularization originating from the retina and/or optic disk in patients with diabetes mellitus. The role of vascular endothelial growth factor appears to be central in the pathogenesis of proliferative diabetic retinopathy. Advanced glycation end products are important in the development of vitreous abnormalities in proliferative diabetic retinopathy. The majority of the neovascular membranes are adherent to the posterior vitreous cortex. When the posterior hyaloid exerts traction, the edges of the neovascular complex are pulled forward, resulting in vitreous hemorrhage. Tractional and/or rhegmatogenous retinal detachments can occur. The Diabetic Retinopathy Study demonstrated the ability of panretinal photocoagulation to reduce the rate of severe visual loss by 50% for eyes with high-risk characteristics, defined as neovascularization originating from the optic disk > 1/3 disk diameter, any neovascularization originating from the optic disk with hemorrhage, and neovascularization originating from the retina with vitreous hemorrhage. The Early Treatment Diabetic Retinopathy Study showed that patients with type II diabetes mellitus who were older than 40 with severe nonproliferative diabetic retinopathy (defined as hemorrhages in four quadrants, venous beading in two quadrants, or intraretinal microvascular abnormalities in one quadrant) also benefited from early panretinal photocoagulation. The Diabetic Retinopathy Vitrectomy Study showed that early vitrectomy (within 6 months of onset of vitreous hemorrhage) was associated with better results in type I diabetes mellitus patients only. The goals of vitreous surgery are to remove the vitreous, including the posterior hyaloid, and to relieve traction from fibrovascular tissue. Delamination and segmentation techniques have been used in the excision of fibrovascular growth on the internal limiting membrane and extending into the vitreous. Panretinal photocoagulation is an integral component of vitrectomy for proliferative diabetic retinopathy. Anti-vascular endothelial growth factor agents may be used in addition to laser as an adjunct to reduce the risk of neovascularization. Vitrectomy surgery may have intraoperative and postoperative complications, including cataract, anterior hyaloidal fibrovascular proliferation, fibrovascular ingrowth, retinal detachment, and recurrent vitreous hemorrhage. Visual potential depends on the preoperative and postoperative status of the macula, as well as on retinal perfusion and the health of the optic nerve. With the improvement in instruments, techniques, and drugs, the results of vitrectomy in proliferative diabetic retinopathy are improving.
增殖性糖尿病视网膜病变的特征是糖尿病患者视网膜和/或视盘出现新生血管。血管内皮生长因子在增殖性糖尿病视网膜病变的发病机制中似乎起着核心作用。晚期糖基化终产物在增殖性糖尿病视网膜病变玻璃体异常的发生发展中起重要作用。大多数新生血管膜附着于玻璃体后皮质。当后玻璃体膜产生牵拉时,新生血管复合体的边缘被向前牵拉,导致玻璃体出血。可发生牵拉性和/或孔源性视网膜脱离。糖尿病视网膜病变研究表明,对于具有高危特征的眼睛,全视网膜光凝能够将严重视力丧失的发生率降低50%,高危特征定义为视盘新生血管>1/3视盘直径、视盘任何新生血管伴有出血以及视网膜新生血管伴有玻璃体出血。早期糖尿病视网膜病变研究表明,年龄大于40岁且患有严重非增殖性糖尿病视网膜病变(定义为四个象限有出血、两个象限有静脉串珠样改变或一个象限有视网膜内微血管异常)的II型糖尿病患者也能从早期全视网膜光凝中获益。糖尿病视网膜病变玻璃体切除术研究表明,早期玻璃体切除术(在玻璃体出血发生后6个月内)仅对I型糖尿病患者有更好的效果。玻璃体手术的目标是切除玻璃体,包括后玻璃体膜,并解除纤维血管组织的牵拉。分层和分割技术已用于切除内界膜上并延伸至玻璃体的纤维血管增生。全视网膜光凝是增殖性糖尿病视网膜病变玻璃体切除术不可或缺的组成部分。除激光外,抗血管内皮生长因子药物可作为辅助药物用于降低新生血管形成的风险。玻璃体切除手术可能有术中及术后并发症,包括白内障、前玻璃体纤维血管增生、纤维血管长入、视网膜脱离和复发性玻璃体出血。视觉潜能取决于黄斑术前和术后的状态,以及视网膜灌注和视神经的健康状况。随着器械、技术和药物的改进,增殖性糖尿病视网膜病变玻璃体切除术的效果正在改善。